대한임상검사과학회지 (Korean Journal of Clinical Laboratory Science)

  • 제54권1호
  • /
  • Pages.38-48
  • /
  • 2022
  • /
  • 1738-3544(pISSN)
  • /
  • 2288-1662(eISSN)
대한임상검사과학회 (Korean Society for Clinical Laboratory Science)
권호 표지
DOI QR코드

DOI QR Code

CEA 발현 마우스 종양모델에서 Cyclophosphamide와 수지상세포 백신의 병합치료에 의한 상승적인 항종양 효과

Synergistic Anti-Tumor Effect by the Combination of Cyclophosphamide and Dendritic Cell Vaccination in Murine Tumor Model that CEA Expressing

  • 박미영 (수원과학대학교 임상병리과)
  • Park, Mi-Young (Department of Clinical Laboratory Science, Suwon Science College)
  • 투고 : 2021.11.09
  • 심사 : 2021.12.24
  • 발행 : 2022.03.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Carcinoembryonic antigen (CEA)는 다양한 종양에서 발현되는 자가 항원으로 면역치료에서 강력한 표지 인자이며 면역치료를 위한 표적 종양항원으로 널리 알려져 있다. 그러나 수지상세포 단독 치료는 동물모델에서 종양의 발생을 억제하는 데 효과가 있지만 이미 확립된 종양을 제거하는 데는 한계가 있다. 본 연구에서는 항종양 면역 효과를 증가시키기 위하여 화학치료제인 cyclophosphamide (CYP)와 종양 특이 면역치료법인 수지상세포 백신의 병합치료 효과를 CEA를 발현하는 마우스 종양 모델에서 검증하였다. 종양세포 주입 후 2일 소종양군과 10일 대종양군에서 CYP의 항종양 효과를 비교한 결과, 소종양군에서는 100 mg/kg에서 뚜렷한 종양 성장의 억제 효과가 관찰되었지만 대종양군에서는 약한 억제 효과가 관찰되어 본 연구에서는 대종양군을 병합치료의 적합한 모델로 설정하였다. CYP 와 수지상세포 백신의 병합치료(화학면역치료) 시 종양항원 특이 면역반응이 증가되었을 뿐만 아니라 상승적인 항종양 효과가 나타났다. 또한 CYP 치료에서 나타나는 체중 감소 및 조절 T세포와 골수유래 억제세포의 증가에 의한 면역억제는 화학면역치료에 의해 개선되었다. 항원 특이 면역치료를 병합한 화학면역치료가 화학치료의 부작용을 감소시키고 항종양 효과를 증가시킬 수 있는 치료 전략이 될 수 있을 것이다.

Carcinoembryonic antigen (CEA) is an oncofetal antigen primarily detected in the peripheral blood of cancer patients, particularly in those with colorectal cancer. CEA is considered a valuable target for antigen-specific immunotherapy. In this study, we induced the anti-tumor immunity for CEA through the administration of a dendritic cell (DC) vaccine. However, there was a limitation in inducing tumor regression in the DC vaccinated mice. To enhance the efficacy of anti-tumor immunity in MC38/CEA2 tumor-bearing mice, we evaluated the effects of DC vaccine in combination with cyclophosphamide (CYP). Administration of CYP 100 mg/kg in mice resulted in significant inhibition of tumor growth in the 2-day tumor model, whereas a lower inhibition of tumor growth was seen in the 10-day tumor model. Therefore, the 10-day tumor model was selected for testing chemo-immunotherapy. The combined CYP and DC vaccine not only increased tumor antigen-specific immune responses but also induced synergistic anti-tumor immunity. Furthermore, the adverse effects of CYP such as weight loss and immunosuppression by regulatory T cells and myeloid-derived suppressor cells showed a significant reduction in the combined chemo-immunotherapy treatment compared with CYP alone. Our data suggest that chemoimmunotherapy with the DC vaccine may offer a new therapeutic strategy to induce a potent anti-tumor effect and reduce the adverse effects of chemotherapy.

키워드

과제정보

This article is based on a part of the first author's master's thesis from University.

참고문헌

  1. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18: 175-196. https://doi.org/10.1038/s41573-018-0006-z
  2. Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019;10:5408. https://doi.org/10.1038/s41467-019-13368-y
  3. Santos PM, Butterfield LH. Dendritic cell-based cancer vaccines. J Immunol. 2018;200:443-449. https://doi.org/10.4049/jimmunol.1701024
  4. Wold WS, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 2013;13: 421-433. https://doi.org/10.2174/1566523213666131125095046
  5. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5:344-366. https://doi.org/10.1002/jcla.1860050510
  6. Alters SE, Gadea JR, Sorich M, O'Donoghue G, Talib S, Philip R. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J Immunother. 1998;21:17-26. https://doi.org/10.1097/00002371-199801000-00002
  7. Schmitz J, Reali E, Hodge JW, Patel A, Davis G, Schlom J, et al. Identification of an interferon-r-inducible carcinoembryonic antigen (CEA) CD8+ T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res. 2002;62:5058-5064.
  8. Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA + metastatic colorectal cancers. Mol Ther. 2017;25:1248-1258. https://doi.org/10.1016/j.ymthe.2017.03.010
  9. Thistlethwaite FC, Gilham DE, Guest RD, Rothwell DG, Pillai M, Burt DJ, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother. 2017;66: 1425-1436. https://doi.org/10.1007/s00262-017-2034-7
  10. Katz SC, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA + liver metastases. Cancer Gene Ther. 2020;27:341-355. https://doi.org/10.1038/s41417-019-0104-z
  11. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin Cancer Res. 2015;21:3149-3159. https://doi.org/10.1158/1078-0432.CCR-14-1421
  12. Asanvaroengchai W, Kotera Y, Mule JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lumphoid recovery. Proc Natl Acad Sci USA. 2002;99:931-936. https://doi.org/10.1073/pnas.022634999
  13. Bitton RJ. Cancer vaccines: a critical review on clinical impact. Curr Opin Mol Ther. 2004;6:17-26.
  14. Fu C, Zhou L, Mi QS, Jiang A. DC-based vaccines for cancer immunotherapy. Vaccines (Basel). 2020;8:706. https://doi.org/10.3390/vaccines8040706
  15. Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol. 2014;27:26-32. https://doi.org/10.1016/j.coi.2014.01.005
  16. Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer. 2019;7:109. https://doi.org/10.1186/s40425-019-0580-6
  17. Timmerman JM, Levy R. Dendritic cell vaccine for cancer immunotherapy. Annu Rev Med. 1999;50:507-529. https://doi.org/10.1146/annurev.med.50.1.507.
  18. Greenberg PD. Adoptive T cell therapy of tumors: mechanism operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281-355. https://doi.org/10.1016/s0065-2776(08)60778-6
  19. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, et al. Importance cyclophosphamide-induced bystander effect on T cell for a successful tumor eradication in response to adoptive transfer in mice. J Clin Invest. 1998;101:429-441. https://doi.org/10.1172/JCI1348
  20. Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer. 2000;87:253-260. https://doi.org/10.1002/1097-0215(20000715)87:2<253::aid-ijc17>3.0.co;2-a
  21. Choi JS, Heo JH, Kim DJ, Namkung SM, Lee TB, Lee MW, et al. Anti-cancer effect of hot water extract from mycelium in germanium-enriched Cordyceps militaris. Korean J Clin Lab Sci. 2017;49:69-78. https://doi.org/10.15324/kjcls.2017.49.2.69
  22. Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metrodosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 2003;63:8408-8413.
  23. Maryam P, Cynthia SC, Laura JG, Catriona M, Catherine L, Kimberly G, et al. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weekly immunogenic tumor model. Cancer Immunol Immunother. 2003;52:739-750. https://doi.org/10.1007/s00262-003-0405-8
  24. Movahedi K, Guilliams M, Bossche JV, Bergh RV, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood. 2008;111:4233-4244. https://doi.org/10.1182/blood-2007-07-099226
  25. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a novel mechanism of CD8+T cell tolerance in cancer. Nat Med. 2007;13:828-835. https://doi.org/10.1038/nm1609
  26. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol. 2005;175:4583-4592. https://doi.org/10.4049/jimmunol.175.7.4583
  27. Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174-185. https://doi.org/10.1016/j.canlet.2020.07.022
  28. Marangoni F, Zhakyp A, Corsini M, Geels SN, Carrizosa E, Thelen M, et al. Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop. Cell. 2021;184: 3998-4015. https://doi.org/10.1016/j.cell.2021.05.027